Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials

Published:2022 Issue: Volume:33 Page:100639
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Sweeney Patrick L.,Jang Albert,Halat Shams K.,Pal Sumanta K.,Barata Pedro C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference51 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors;Delahunt;Mod. Pathol.,1997

3. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study;Saad;Clin Genitourin Cancer,2019

4. Impact of gender in renal cell carcinoma: an analysis of the SEER database;Aron;Eur. Urol.,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma;Journal of Clinical Oncology;2024-09-10

2. Integrated Bioinformatics and Experimental Validation to Identify a Disulfidptosis-Related lncRNA Model for Prognostic Prediction in Papillary Renal Cell Carcinoma;Combinatorial Chemistry & High Throughput Screening;2024-04-18

3. A commentary on ‘Risk factors for incident venous thromboembolism in patients with renal tumor and inferior vena cava tumor thrombus: A retrospective case–control study’;International Journal of Surgery;2024-01-17

4. The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma;Therapeutic Advances in Urology;2024-01

5. Role of anoikis-related gene PLK1 in kidney renal papillary cell carcinoma: a bioinformatics analysis and preliminary verification on promoting proliferation and migration;Frontiers in Pharmacology;2023-06-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3